파멥신 Revenue and Competitors
Estimated Revenue & Valuation
- 파멥신's estimated annual revenue is currently $5.4M per year.
- 파멥신's estimated revenue per employee is $155,000
Employee Data
- 파멥신 has 35 Employees.
- 파멥신 grew their employee count by 9% last year.
파멥신's People
| Name | Title | Email/Phone |
|---|
파멥신 Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is 파멥신?
PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologies such as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibody production technology, and antibody production technology using cancer stem cell library. Since we were established in 2008 we have been devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001. We will constantly develop pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.
keywords:N/A
N/A
Total Funding
35
Number of Employees
$5.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Daejeon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.4M | 44 | -20% | N/A |
#2 | $8.1M | 52 | 4% | N/A |
#3 | $6M | 67 | 5% | N/A |